Image by Freepik
A new Yale School of Medicine and Icahn School of Medicine at Mount Sinai study found that people who have experienced brain fog, confusion, pain, and extreme fatigue for months or longer after being infected with COVID-19 have different immune and hormonal responses to the virus.
These different responses may help scientists pinpoint the origins and maybe solutions for the frequently debilitating condition that has impacted millions worldwide. The U.S. estimates 7.5% of SARS-CoV-2 infections develop long-term COVID.
“If you are a doctor doing routine lab work on these patients, you are not going to find these signals,” said Akiko Iwasaki, Sterling Professor of Immunobiology at Yale and co-senior author of the paper.
The findings appeared in Nature on Sept. 25.
The study examined blood samples from 268 persons who had long-term COVID symptoms for an average of one year, had recovered from COVID-19, or had no past infections. The researchers found substantial changes in circulating antibodies and other immune system cells between long-COVID patients and others.
Long-term COVID patients have higher levels of antibodies that combat non-COVID-19 viruses, including Epstein-Barr virus, a human herpesvirus related to many malignancies. These individuals also had significantly reduced cortisol levels, a stress hormone secreted by the adrenal glands.
The scientists say these data indicate fundamental molecular processes related with chronic COVID, but the variety of individual reactions makes creating treatments difficult.
“There is no ‘silver bullet’ for treating long COVID, because it is an illness that infiltrates complex systems such as the immune and hormonal regulation,” said co-senior author David Putrino, a professor of rehabilitation and human performance at Icahn Mount Sinai and director of the Cohen Center for Recovery From Complex Chronic Illness
Iwasaki said the new findings may contribute in the development of novel diagnostics and treatments.
“Once we have more information on these signals, we can start to think about designing the right trials to treat this condition,” she said.
more recommended stories
CDI Test Shows Early Detection Potential in Alzheimer’sBreakthrough Study Highlights Brain Blood Flow.
Prenatal Chlorpyrifos Exposure and Pediatric Brain ChangesA Growing Concern in Pediatric Neurodevelopment.
Valve Deterioration After TAVI: New Research InsightsThe Growing Role of TAVI in.
FAST Walking Shows Promise in Post-Stroke RehabStroke remains one of the leading.
Legionnaires’ Disease Long-Term Effects on Patient RecoveryPersistent Symptoms and Post-Acute Infection Syndromes.
Brisk Walking: A 15-Minute Daily Habit That Reduces Mortality in Underserved PopulationsA powerful yet simple intervention A.
Vaping and Teen Smoking: UK Study Warns of Rising RisksA new study published in Tobacco.
Targeting Cancer Cell Memory Boosts ChemotherapyResearchers double chemotherapy effectiveness through chromatin.
PFAS Exposure Linked to Increased Type 2 Diabetes RiskInvestigating the Metabolic Impact of Forever.
Gecko-Inspired Nanoparticles Offer New Direction in Localized Cancer TherapyNature-Inspired Nanoparticles Deliver Precision Chemotherapy Researchers.
Leave a Comment